Tofacitinib in the Treatment of Rheumatoid Arthritis-related Interstitial Lung Disease.

NCT05246293 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

60

Enrollment

OTHER_GOV

Sponsor class

Conditions

Rheumatoid Arthritis
Interstitial Lung Disease

Interventions

DRUG: Tofacitinib

Sponsor

National Institute of Respiratory Diseases, Mexico